Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03461783 · ClinicalTrials.gov registry record · NA

Activated Carbon Interphase Effect on Biofilm and Total Bacterial Load

A NA study of Wound Infection, sponsored by Brock Liden, DPM.

Completed
Registry status
NA
Development phase
21
Enrollment target
2
Study locations

NCT03461783: Completed NA study of Wound Infection, sponsored by Brock Liden, DPM.

NCT03461783 is a NA study of Wound Infection that has completed, run by Brock Liden, DPM. The registered enrollment target is 21 participants, below the 376-participant average among 10 other Wound Infection trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03461783, a NA study of Wound Infection, has completed, sponsored by Brock Liden, DPM.

COMPLETED
Registry status
NA
Development phase
21 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this randomized, prospective study is to evaluate how this activated carbon dressing affects the total bacterial load and biofilm in a wound bed in wounds of the lower extremity and foot. We anticipate that the use of Zorflex® Activated Carbon Cloth dressing will maintain the bacterial burden in the wound bed below the level of critical colonization, with potential secondary benefits of pain reduction, decrease in inflammation, and control of odor. Wound bed healing progression/acceleration also will be assessed.

Primary Outcome

Total bacterial load will be measured total colony forming units (CFUs) as determined from laboratory findings

Conditions Studied

Interventions

  • DEVICE Standard of Care
  • DEVICE Zorflex Activated Carbon Dressing

Study Locations (2)

Ohio

  • Circleville Foot & Ankle, LLC - Circleville
  • Hocking Valley Community Hospital - Logan

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2017-06-26
Est. Completion 2019-02-01
Phase NA
Brock Liden, DPM

1 total trials

What the finished NCT03461783 record still lists

NCT03461783 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 376-participant average among 10 other Wound Infection trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Wound Infection appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.

NCT03461783 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT03461783 about?

NCT03461783 is a clinical study titled "Activated Carbon Interphase Effect on Biofilm and Total Bacterial Load". The purpose of this randomized, prospective study is to evaluate how this activated carbon dressing affects the total bacterial load and biofilm in a wound bed in wounds of the lower extremity and foot. We anticipate that the use of Zorflex® Activated Carbon Cloth dressing will maintain the bacteria...

What is the current status of trial NCT03461783?

This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2017-06-26. Estimated completion is 2019-02-01.

What conditions does trial NCT03461783 study?

This clinical trial studies the following conditions: Wound Infection.

What interventions are being tested in trial NCT03461783?

The interventions under investigation include: Standard of Care (DEVICE), Zorflex Activated Carbon Dressing (DEVICE).

Who is sponsoring clinical trial NCT03461783?

This trial is sponsored by Brock Liden, DPM, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03461783 being conducted?

This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Wound Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03461783's enrollment target sits among peer trials

21 10th of 10 higher than 1 of 10 other Wound Infection trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Wound Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03461783, the US trial registry maintained by the National Library of Medicine. NCT03461783 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.